Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum 299v + galacto-oligosaccharides is a synbiotic combination consisting of the probiotic strain Lactobacillus plantarum 299v (LP299V) and the prebiotic galacto-oligosaccharides (GOS). LP299V is a well-documented Gram-positive bacterium that colonizes the human intestinal mucosa by binding to mannose-specific receptors, thereby enhancing the intestinal barrier and competing with pathogenic bacteria. Galacto-oligosaccharides are non-digestible carbohydrates that serve as a substrate for beneficial gut bacteria, selectively promoting the growth of Bifidobacteria and Lactobacilli. This combination is primarily utilized to manage symptoms of irritable bowel syndrome (IBS), such as abdominal pain, bloating, and irregular bowel movements, by modulating the gut microbiota and reducing intestinal inflammation. It is typically marketed as a dietary supplement or nutraceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus plantarum 299v + galacto-oligosaccharides.